Days after FDA Commissioner Marty Makary appeared to malign uniQure’s AMT-130 in an interview with CNBC, the agency confirmed ...

RGX-121 was rejected in early February, with Regenxbio listing the primary reasons given by the FDA as concerns about the ability to properly define a patient population, the use of a natural history ...

In a strikingly blunt briefing, a senior FDA official accused uniQure of pushing “distorted” data to mask a “failed” therapy ...

While the FDA appears to be adamant that uniQure conduct a sham surgery–controlled Phase 3 trial before AMT-130 can be ...

Off-campus mental health resources include a 24/7 hotline, outpatient therapy and an intensive outpatient program.

Why do Employee Assistance Programs (EAPs) often fall short of solving burnout in the workplace? In an article on HelloNation ...

Agency staff "strongly recommended" a sham surgery-controlled trial be conducted before an approval filing, a stance one analyst called a "worst case scenario" for UniQure.

NEW YORK, NY / ACCESS Newswire / March 6, 2026 / Emerging Growth Research today announced the release of its Flash ...

Shares of uniQure N.V. QURE plunged 31.8% in a week, primarily after the company announced a disappointing regulatory update ...

Our son, who is in college, began losing his hair in high school. It could be genetic, but this does not run in the family. Related Articles. Asking Eric: Do strangers ...

Pediatric brain tumors represent a significant health challenge as they are the second most common form of childhood cancer and a leading cause of ...

Cancer remains a leading cause of global morbidity and mortality, and conventional therapeutic strategies are often limited by poor tumor selectivity, ...